title: Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
abstract: Clinical trial results indicate that lenalidomide, an immunomodulatory drug, is a promising treatment in relapsed/refractory non-Hodgkin lymphoma (NHL). This retrospective multicenter study was conducted in patients with relapsed/refractory NHL treated with lenalidomide monotherapy through a Named Patient Program in Italy. Principal endpoints were overall response rate (ORR), safety and overall survival (OS). The ORR in 64 evaluable patients was 42.2% and was similar among patients receiving 10, 15 or 25 mg/day lenalidomide. Response rates in patients with mantle cell, diffuse large B-cell and follicular lymphoma were 45.5%, 42.1% and 20%, respectively. Among patients who responded to most recent prior therapy, ORR was 50.0% versus 36.8% in patients with refractory NHL. Mean duration of response in patients receiving any lenalidomide dose was 10.5 months; 1-year progression-free survival and OS were 50.3% and 82.6%, respectively. These findings suggest that lenalidomide is effective and safe for heavily pretreated patients with NHL in the clinical setting.
authors.affiliation: Institute of Haematology "L. e A. Seràgnoli", University of Bologna , Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Luigi
authors.initials: L
authors.lastname: Rigacci
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Cox
authors.forename: Liliana
authors.initials: L
authors.lastname: Devizzi
authors.forename: Alberto
authors.initials: A
authors.lastname: Fabbri
authors.forename: Alfonso
authors.initials: A
authors.lastname: Zaccaria
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Alice
authors.initials: A
authors.lastname: Di Rocco
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rossi
authors.forename: Sergio
authors.initials: S
authors.lastname: Storti
authors.forename: Pier Paolo
authors.initials: PP
authors.lastname: Fattori
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.forename: Sante
authors.initials: S
authors.lastname: Tura
authors.forename: Umberto
authors.initials: U
authors.lastname: Vitolo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007558:Italy; D000077269:Lenalidomide; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D056687:Off-Label Use; D012189:Retrospective Studies; D015996:Survival Rate; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Lenalidomide; non-Hodgkin lymphoma; off-label; refractory; relapsed